The presence of CD8+ tumor-infiltrating lymphocytes (TILs) within the tumor is often correlated with improved prognosis and survival in colon cancer patients. CD8+ T cells are essential for the immune system's ability to recognize and eliminate emerging cancer cells, preventing tumor development and progression. Thus, CD8+ T cells are central to the immune response against colon cancer, and their activity is a key determinant of patient outcomes. Immuno-oncology strategies, including ICIs, adoptive cell transfer, cancer vaccines, and oncolytic viruses, leverage the power of CD8+ T cells to combat colon cancer. Ongoing research aims to enhance the effectiveness of these therapies by improving T cell infiltration, overcoming immune evasion mechanisms, and personalizing treatment approaches based on individual tumor profiles. With an average fold increase of nearly 3.5-fold for the period 2020-2022, the CD8 | colon cancer concept pair is among the fastest growing ones (Figure ).